Two Healthcare Stocks That Insiders Are Buying

Over the past couple of days, the healthcare sector has witnessed plenty of insider activity, which should not be overlooked. In this article, I will examine two companies in this segment..

First off is Owens & Minor, Inc. (NYSE:OMI), a $2.1 billion market cap Fortune 500 company that provides third-party logistics (3PL) services to manufacturers and suppliers of healthcare and life-science products. On May 7th, Richard Meier, Executive Vice President and Chief Financial Officer, acquired 2,500 shares of Common Stock for $32.50 per share. Following this transaction, Mr. Meier holds 40,566 shares of the company, worth more than $1.3 million.

On top of Mr. Meier’s bullishness, more than a dozen major hedge funds hold long positions in the stock. The largest hedge fund shareholder, Chuck Royce’s Royce & Associates, holds 1.83 million shares of the company. Joel Greenblatt (Gotham Asset Management) also seems to feel confident about the company’s future, as he last increased his stakes by 69% to 373,228 shares (in Q4 2013). Similar is Ken Griffin, David Dreman and Mario Gabelli´s case: they all declared having added shares of the company to their portfolios over the last quarter that they reported.

Despite the positive sentiment amongst insiders and funds, analysts do not seem to like this company. In spite of Owens & Minor’s above average margins and return on assets, coupled with a cheap valuation, most analysts rate the stock as a “hold” or “underperform” case, and expect it to deliver average annual EPS growth rates around 9% over the next five years –compared to an industry mean of 14%-15%.

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)

The second healthcare company I would like to refer to is Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a $976 million market cap biopharmaceutical company focused on the development and commercialization of its product, lomitapide. Opposite to Owens & Minor, Aegerion does not look good on paper. While it boasts negative margins and returns, it still trades above the biotech industry average valuations. However, analysts seem to love the stock, and recommend buying it. Consensus estimates point towards average annual EPS growth rates around 1,253% over the next five years.

In addition to analysts, both hedge funds and insiders seem to feel bullish about this stock. On Thursday May 8th, Marc D. Beer, Chief Executive Officer, acquired 30,000 shares of Common Stock for prices ranging from $34.64 to $35.35 per share, inclusive. He now holds 33,000 shares directly, and another 246,462 shares, indirectly. Moreover, the two largest hedge fund shareholders, Andreas Halvorsen´s Viking Global, and Arthur B Cohen and Joseph Healey Healthcor Management Lp, have been increasing their stakes at the company. The latter doubled its bets over the last reported quarter, to 850,000 shares; Viking Global increased its holdings by 18%, to 881,333 shares.

 

Disclosure: Javier Hasse holds no position in any stocks mentioned

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!